17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts - PubMed (original) (raw)

Fuzhong F Zheng, Maria Drobnjak, Pamela N Münster, Brian Higgins, David Verbel, Glenn Heller, William Tong, Carlos Cordon-Cardo, David B Agus, Howard I Scher, Neal Rosen

Affiliations

PMID: 12006510

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts

David B Solit et al. Clin Cancer Res. 2002 May.

Abstract

Purpose: Ansamycin antibiotics, including 17allylamino-17-demethoxygeldanamycin (17-AAG), inhibit Hsp90 function and cause the selective degradation of signaling proteins that require this chaperone for folding. Because mutations in the androgen receptor (AR) and activation of HER2 and Akt may account, in part, for prostate cancer progression after castration or treatment with antiandrogens, we sought to determine whether an inhibitor of Hsp90 function could degrade these Hsp90 client proteins and inhibit the growth of prostate cancer xenografts with an acceptable therapeutic index.

Experimental design: The effect of 17-AAG on the expression of Hsp90 regulated signaling proteins in prostate cancer cells and xenografts was determined. The pharmacodynamics of target protein degradation was associated with the toxicology and antitumor activity of the drug.

Results: 17-AAG caused the degradation of HER2, Akt, and both mutant and wild-type AR and the retinoblastoma-dependent G1 growth arrest of prostate cancer cells. At nontoxic doses, 17-AAG caused a dose-dependent decline in AR, HER2, and Akt expression in prostate cancer xenografts. This decline was rapid, with a 97% loss of HER2 and an 80% loss of AR expression at 4 h. 17-AAG treatment at doses sufficient to induce AR, HER2, and Akt degradation resulted in the dose-dependent inhibition of androgen-dependent and -independent prostate cancer xenograft growth without toxicity.

Conclusions: These data demonstrate that, at a tolerable dose, inhibition of Hsp90 function by 17-AAG results in a marked reduction in HER2, AR, and Akt expression and inhibition of prostate tumor growth in mice. These results suggest that this drug may represent a new strategy for the treatment of prostate cancer.

PubMed Disclaimer

Comment in

Cited by

Curcumin derivative C212 inhibits Hsp90 and eliminates both growing and quiescent leukemia cells in deep dormancy.
Liu B, Shen Y, Huang H, Croce KD, Wu M, Fan Y, Liu Y, Xu J, Yao G. Liu B, et al. Cell Commun Signal. 2020 Sep 29;18(1):159. doi: 10.1186/s12964-020-00652-4. Cell Commun Signal. 2020. PMID: 32993709 Free PMC article.
Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.
Schulz R, Marchenko ND, Holembowski L, Fingerle-Rowson G, Pesic M, Zender L, Dobbelstein M, Moll UM. Schulz R, et al. J Exp Med. 2012 Feb 13;209(2):275-89. doi: 10.1084/jem.20111117. Epub 2012 Jan 23. J Exp Med. 2012. PMID: 22271573 Free PMC article.
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.
Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie A, Hamburger AW. Zhang Y, et al. Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9890-5. doi: 10.1073/pnas.0503829102. Epub 2005 Jun 30. Proc Natl Acad Sci U S A. 2005. PMID: 15994225 Free PMC article.
Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.
Seaton A, Maxwell PJ, Hill A, Gallagher R, Pettigrew J, Wilson RH, Waugh DJ. Seaton A, et al. Br J Cancer. 2009 Nov 3;101(9):1620-9. doi: 10.1038/sj.bjc.6605356. Epub 2009 Oct 6. Br J Cancer. 2009. PMID: 19809428 Free PMC article.
Heterogeneous Responses and Isoform Compensation the Dim Therapeutic Window of Hsp90 ATP-Binding Inhibitors in Cancer.
Tang X, Chang C, Mosallaei D, Woodley DT, Schönthal AH, Chen M, Li W. Tang X, et al. Mol Cell Biol. 2022 Feb 17;42(2):e0045921. doi: 10.1128/MCB.00459-21. Epub 2021 Dec 6. Mol Cell Biol. 2022. PMID: 34871064 Free PMC article.

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts - PubMed (original) (raw)